TAK

TAK

USD

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$13.660+0.060 (0.441%)

实时价格

Healthcare
Drug Manufacturers - Specialty & Generic
日本

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$13.600

最高价

$13.680

最低价

$13.560

成交量

2.79M

公司基本面

市值

43.2B

所属行业

Drug Manufacturers - Specialty & Generic

国家/地区

Japan

交易统计

平均成交量

2.88M

交易所

NYQ

货币

USD

52周价格范围

最低价 $12.8当前价 $13.660最高价 $15.69

相关新闻

BusinessWire

New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization

Findings Reinforce QDENGA's Long-Term Safety Profile and Two-Dose Vaccination Schedule QDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease Exposure Takeda is

查看更多
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
BusinessWire

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year

First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% at Actual Exchange Rates (AER), Impacted by Generic Erosion of VYVANSE® and FX Headwind Core Operating Profit Declined 8.8% at CER in the

查看更多
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
BusinessWire

HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation

Dedicated Devices for HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Reduce the Number of Steps and Ancillary Supplies Compared to a Pooling Bag When Preparing the HYQVIA

查看更多
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
PR Newswire

Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market

Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation IO and ADC...

查看更多
Innovent Biologics Announces Global Strategic Partnership with Takeda to Bring Innovent's Next Gen IO Backbone Therapy and ADC Molecules to the Global Market
BusinessWire

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage Program Takeda to Lead

查看更多
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors